Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5(6):957–71.
Article
CAS
Google Scholar
Fahrmann JF, Schmidt CM, Mao X, Irajizad E, Loftus M, Zhang J, et al. Lead-Time Trajectory of CA19–9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology. 2021;160(4):1373-83 e6.
Article
CAS
Google Scholar
Sakamoto K, Haga Y, Yoshimura R, Egami H, Yokoyama Y, Akagi M. Comparative effectiveness of the tumour diagnostics, CA 19–9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut. 1987;28(3):323–9.
Article
CAS
Google Scholar
Hanke B, Riedel C, Lampert S, Happich K, Martus P, Parsch H, et al. CEA and CA 19–9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol. 2001;12(2):221–6.
Article
CAS
Google Scholar
Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18):2897–902.
Article
CAS
Google Scholar
Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA 19–9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9(2):132–8.
Article
CAS
Google Scholar
Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chin J Cancer Res. 2019;31(1):117–34.
Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis. Treatment and Follow-up Ann Oncol. 2020;31(10):1291–305.
CAS
PubMed
Google Scholar
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28(suppl_4):iv22-iv40.
Filella X, Molina R, Grau JJ, Piqué JM, Garcia-Valdecasas JC, Astudillo E, et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg. 1992;216(1):55–9.
Article
CAS
Google Scholar
Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19–9 serum levels in colorectal cancer. Anticancer Res. 2000;20(6d):5195–8.
CAS
PubMed
Google Scholar
Nozawa H, Ishihara S, Kawai K, Hata K, Kiyomatsu T, Tanaka T, et al. A high preoperative carbohydrate antigen 19–9 level is a risk factor for recurrence in stage II colorectal cancer. Acta Oncol. 2017;56(5):634–8.
Article
CAS
Google Scholar
Yu H, Son GM, Joh YG. The clinical significance of preoperative serum levels of carbohydrate antigen 19–9 in colorectal cancer. J Korean Surg Soc. 2013;84(4):231–7.
Article
CAS
Google Scholar
Zhou W, Yang F, Peng J, Wang F, Lin Y, Jiang W, et al. High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy. J Cancer. 2019;10(16):3810–8.
Article
Google Scholar
Sefrioui D, Beaussire L, Gillibert A, Blanchard F, Toure E, Bazille C, et al. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC). Br J Cancer. 2021;125(5):725–33.
Article
CAS
Google Scholar
Lin PC, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK, et al. Carbohydrate antigen 19–9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. Int J Colorectal Dis. 2012;27(10):1333–8.
Article
Google Scholar
Stiksma J, Grootendorst DC, van der Linden PW. CA 19–9 as a marker in addition to CEA to monitor colorectal cancer. Clin Colorectal Cancer. 2014;13(4):239–44.
Article
Google Scholar
Liu JM, Wang YY, Liu W, Xu D, Wang K, Xing BC. Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy. Int J Colorectal Dis. 2021;36(4):767–78.
Article
Google Scholar
Shin JK, Kim HC, Lee WY, Yun SH, Cho YB, Huh JW, et al. High preoperative serum CA 19–9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis. Ann Surg Treat Res. 2019;96(3):107–15.
Article
CAS
Google Scholar
National-Comprehensive-Cancer-Network(NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer.(Version 4.2021). Fort Washington, PA: NCCN. 2021.
National-Comprehensive-Cancer-Network(NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Rectal Cancer.(Version 1.2021). Fort Washington, PA: NCCN. 2021.
Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O’Brien M, et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol. 1995;6(6):581–7.
Article
CAS
Google Scholar
Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum. 2004;47(2):227–32.
Article
Google Scholar
Abe S, Kawai K, Ishihara S, Nozawa H, Hata K, Kiyomatsu T, et al. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19–9 in stage IV colorectal cancer patients after R0 resection. J Surg Res. 2016;205(2):384–92.
Article
CAS
Google Scholar
Yuan R, Chen Y, He X, Wu X, Ke J, Zou Y, et al. CCL18 as an independent favorable prognostic biomarker in patients with colorectal cancer. J Surg Res. 2013;183(1):163–9.
Article
CAS
Google Scholar
Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246(6):1047–51.
Article
Google Scholar
Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Toyokawa T, et al. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. Anticancer Res. 2014;34(7):3753–8.
PubMed
Google Scholar
Reichling C, Taieb J, Derangere V, Klopfenstein Q, Le Malicot K, Gornet JM, et al. Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. Gut. 2020;69(4):681–90.
Article
CAS
Google Scholar
Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. J Natl Cancer Inst. 2018;110(8):803–11.
Article
Google Scholar
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453–7.
Article
Google Scholar
Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551–61.
Article
CAS
Google Scholar
Harrell FE. Aspects of Fitting Regression Models. Regression Modeling Strategies. New York, NY: Springer, 2001.
Ha ID, Sylvester R, Legrand C, MacKenzie G. Frailty modelling for survival data from multi-centre clinical trials. Stat Med. 2011;30(17):2144–59.
Article
Google Scholar
Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, et al. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncol. 2018;4(3):309–15.
Article
Google Scholar
Hermunen K, Soveri LM, Boisen MK, Mustonen HK, Dehlendorff C, Haglund CH, et al. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer. Acta Oncol. 2020;59(12):1416–23.
Article
CAS
Google Scholar
Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348–60.
Article
CAS
Google Scholar
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.
Article
CAS
Google Scholar
Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol. 2017;39(6):1010428317692231.
Article
Google Scholar
Kawai S, Suzuki K, Nishio K, Ishida Y, Okada R, Goto Y, et al. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes. Int J Cancer. 2008;123(12):2880–4.
Article
CAS
Google Scholar